Cover Image
市場調查報告書

全球主要13個國家市場上肌少症患者數的預測

Sarcopenia Forecast in 13 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 371050
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
全球主要13個國家市場上肌少症患者數的預測 Sarcopenia Forecast in 13 Major Markets 2016-2026
出版日期: 2016年09月22日 內容資訊: 英文 50 Pages
簡介

本報告提供全球主要13個國家市場上肌少症的罹患情形調查,肌少症患者數及肌少症肥胖患者數的變化與預測,各級的明細,疾病概要,危險因素,疾病診斷預後,主要的症狀和並存症等彙整資料。

調查對象國家

  • 美國
  • 法國
  • 加拿大
  • 德國
  • 義大利
  • 西班牙
  • 巴西
  • 印度
  • 英國
  • 澳洲
  • 日本
  • 韓國
  • 中國

目錄

  • 簡介
  • 疾病的原因
  • 風險要素與預防
  • 疾病診斷
  • 地區、民族的差異
  • 疾病的預後和臨床過程
  • 疾病相關的主要並存症/特徵
  • 患者數的定量化的方法
  • 肌肉減少症的患病人數
  • 肌肉減少症的患者的特徵
    • 各級
    • 肌少症肥胖
  • 本文中的簡稱
  • 關於相關分析、資料庫
  • 註腳
  • 附錄

圖表一覽

目錄
Product Code: SCPN0010916

image1

Sarcopenia is defined as the progressive and generalised loss of skeletal muscle as a natural result of the ageing process. Loss of muscle mass tends to start any time after the age of 30, but the accompanying loss of strength increases exponentially with age. Sarcopenia is characterised by atrophy of (predominantly) fast-twitch muscle fibres with accumulation of fat within muscle tissue. It is thought that the Akt pathway, which drives protein turn-over in the muscle, becomes tipped toward net loss of muscle. Higher activation of the Akt pathway and consequently loss of muscle mass with age has been linked with: decrease in testosterone levels, decreased synthetic capacity of muscle ("anabolic resistance"), increased insulin resistance, decreased IGF-1 levels.

Patients with sarcopenia have an increased risk of adverse outcomes such as physical disability, poorer quality of life, hospitalisation and mortality.

This report provides the current prevalent population for Sarcopenia across 13 Major Markets (USA, France, Canada, Germany, Italy, Spain, Brazil, India, UK, Australia, Japan, Korea and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Sarcopenia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Diseases associated with sarcopenia:

  • Obesity
  • Type 2 diabetes
  • Metabolic syndrome and insulin resistance

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Sarcopenia's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Sarcopenia and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Sarcopenia's prevalent population.
  • Identify sub-populations within Sarcopenia which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Sarcopenia patients.

Coverage

AU, BR, CA, CN, FR, DE, IN, IT, JP, KR, ES, UK, US

image2

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Prevalence for Sarcopenia

Features of Sarcopenia Patients

  • Sarcopenia by Class
  • Sarcopenic Obesity

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Tables

  • Sarcopenia categories by cause
  • Measurements of muscle mass, strength and function in research and practice
  • Criteria for the diagnosis of sarcopenia
  • EWGSOP conceptual stages of sarcopenia
  • Prevalence of Sarcopenia, total (000s)
  • Prevalence of Sarcopenia , males (000s)
  • Prevalence of Sarcopenia, females (000s)
  • Sarcopenia by class, total (000s)
  • Sarcopenic obesity by class, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • USA Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • France Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • France Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • Canada Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • Canada Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • Germany Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • Germany Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • Italy Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • Italy Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • Spain Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • Spain Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • India Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • India Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • UK Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • UK Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • Australia Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • Australia Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • Japan Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • Japan Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • Korea Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • Korea Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
  • China Prevalence of Sarcopenia by 5-yr age cohort, males (000s)
  • China Prevalence of Sarcopenia by 5-yr age cohort, females (000s)
Back to Top